We use cookies to ensure that we give you the best experience on your website. If you continue without changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Protection when you need it. Patency when you don’t.
Re-Inventing PE Protection.
BTG Vascular sets the standard for vascular therapies through evidence based innovation, predictable and cost-effective procedures, and strong safety profiles that improve patient outcomes and help make the most challenging cases easier.
Fast, intraluminal occlusion crossing. BTG Crossing Devices provide physician support to make tough crossings easier. Staying true lumen opens revascularization possibilities, improves patient safety, comfort and healthcare costs.
Resource of case studies, clinical trial data and in-servicing videos for the family of EKOS™ devices.
Treat More Veins
EKOS OPTALYSE Study Summary
The EKOS device with Acoustic Pulse Thrombolysis™ is the first endovascular device cleared by the FDA and CE marked for the treatment of Pulmonary Embolism (PE).
The first and only FDA approved foam to the treatment of the great saphenous vein (GSV) system.1,2
EKOS™ is setting the standard for PE treatment safety and efficacy, again. With the EKOS™ treatment’s successful very-low dose and short duration regimens in the OPTALYSE PE trial and favorable long term data results point to a paradigm-changing approach for PE treatment.
Veins aren’t always a straight path. Neither is treatment. Now with favorable reimbursement, it’s a reliable tool for discerning vein specialists who want to treat the broadest range of anatomies.1,2
15 Nov AIM
17 Nov VEITH
16 Nov BSIR - British Society of Interventional...
03 Dec Arizona Patients Successfully Receive th...
20 Nov Recommended Cash Offer for BTG plc by Bo...
13 Nov BTG plc: Interim Results 2018
Information
15 Jun One-year results of ACCESS PTS study bri...
28 Apr OPTALYSE PE Results Presented at Society...
25 Aug Health Canada approves radiopaque bead f...